Novo Nordisk's GLP-1 pill has reignited the competition in the GLP-1 space. But you can sidestep that drama by buying this surgical robotics pioneer.
Awareness and prescribing of the Wegovy pill for weight loss surge among primary care physicians and endocrinologists following its January launch. Awareness and prescribing of the Wegovy pill for weight loss surge among primary care physicians and endocrinologists following its January launch.
Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and sweeping changes to vaccine policy.
HONG KONG, Feb. 19, 2026 /PRNewswire/ -- As the multi-billion-dollar obesity treatment market continues to search for new therapeutic approaches beyond GLP-1–based treatments, Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, recently reported additional progress related to its proprietary, non-hallucinogenic neuroplastogen, MEAI. In a world where obesity affects over a billion people globally, the search for truly transformative weight loss solutions has never been more urgent.
Online telehealth company Hims & Hers Health , seeking growth drivers as its original sexual-health franchises matured, may have overstepped with a risky launch of weight-loss pills that drew swift blowback from Danish drugmaker Novo Nordisk and U.S. regulators.
Flowers Foods remains a Strong Buy, with deep value and recovery potential despite near-term consumer headwinds and soft 2026 guidance. FLO's robust free cash flow and solid balance sheet underpin intrinsic value, even as EBITDA and net sales guidance reflect ongoing category and inflationary pressures. Although sustainable, the dividend should be under review; a cut could unlock capital for debt repayment or buybacks, potentially enhancing long-term shareholder value despite near-term pressure.
Next-generation rhCollagen-based technology aims to restore facial structure and skin quality in patients experiencing volume depletion linked to GLP-1 weight-loss therapies REHOVOT, Israel, Feb. 17, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen), today announced the strategic positioning of its photocurable dermal filler platform to address facial volume loss associated with rapid weight reduction, including patients treated with GLP-1 therapies. The expanding use of GLP-1 therapies for metabolic health and weight management has created a growing population experiencing loss of facial fat, skin laxity, and structural deflation - commonly referred to in the medical community as weight-loss-related facial volume depletion.
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that it will release its fourth-quarter and full-year 2025 financial results before the market opens on Friday, February 27, 2026. At 10:00 a.m. ET, the Partnership will conduct a conference call for investors and analysts hosted by Eric Slifka, President and Chief Executive Officer, Gregory B. Hanson, Chief Financial Officer, and Mark Romaine, Chief Operating Officer. The ca.
Among early users of Novo Nordisk's new Wegovy weight-loss pill, 36% had no prior experience taking a GLP-1 medication, a new study from the health data firm Truveta found.
Expands Wellness Platform with Targeted GLP-1 Support Products Focused on Fiber, Vitality, and Protein Kick. Sports Nutrition® Expands with New Flavor Innovations Across Protein and Pre- and Post-Workout Lines BELVIDERE, NJ, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leading provider of controlled environment agriculture (CEA) solutions and sustainable, locally grown organic produce, today announced that it will debut JEALOUSY, a clean-label GLP-1 support system developed using the Company's Farm to Formula® approach at ECRM's Total Wellness: GLP-1, Weight Management, Nutrition & Vitamin Session, taking place February 10–12, 2026, at the Hyatt Regency Chicago O'Hare in Rosemont, Illinois.
